Molecular and functional interactions among monocytes/macrophages and smooth muscle cells and their relevance for atherosclerosis

Critical Reviews in Eukaryotic Gene Expression

Volumn 24, Issue 4, 2014, Pages 341-355

  Butoi, Elena ^a   Gan, Ana Maria ^a   Manduteanu, Ileana ^a  

^a INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

Author keywords

Atherosclerosis; Cell crosstalk; Fractalkine; Monocytes macrophages; Smooth muscle cells

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; PROTEIN; PROTEIN VLA 4; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

APOPTOSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL COMMUNICATION; CELL FUNCTION; CELL INTERACTION; HUMAN; INFLAMMATORY CELL; MACROPHAGE; MACROPHAGE ACTIVATION; MOLECULAR INTERACTION; MONOCYTE; NONHUMAN; PHENOTYPE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; ANIMAL; BLOOD VESSEL; CYTOLOGY; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; ATHEROSCLEROSIS; BLOOD VESSELS; CELL COMMUNICATION; HUMANS; MACROPHAGES; MONOCYTES; MYOCYTES, SMOOTH MUSCLE;

EID: 84908160993     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukaryotGeneExpr.2014012157     Document Type: Article

References (71)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74.
2. Manduteanu I, Simionescu M. Inflammation in atherosclerosis: a cause or a result of vascular disorders? J Cell Mol Med. 2012;16(9):1978–90.
3. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol. 2010;7(2):77–86.
4. Clarke MCH, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD, Bennett MR. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med. 2006 Sep;12(9):1075–80.
5. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8(12):958–69.
6. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175–84.
7. Lambrecht BN. Alveolar macrophage in the driver’s seat. Immunity. 2006;24(4):366–8.
8. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6(7):508–19.
9. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13(10):709–21.
10. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3):204–12.
11. Boyle JJ, Bowyer DE, Weissberg PL, Bennett MR. Human blood-derived macrophages induce apoptosis in human plaque-derived vascular smooth muscle cells by Fas-ligand/Fas interactions. Arterioscler Thromb Vasc Biol. 2001;21(9):1402–7.
12. Lacolley P, Regnault V, Nicoletti A, Li Z, Michel JB. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res. 2012;95(2):194–204.
13. Zawada AM, Rogacev KS, Schirmer SH, Sester M, Böhm M, Fliser D, Heine GH. Monocyte heterogeneity in human cardiovascular disease. Immunobiology. 2012;217(12):1273–84.
14. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman K, Sozzani S, Strobl H, Zembala M, Austyn JM, Lutz MB. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116(16):e74–80.
15. Landsman L, Bar-On L, Zernecke A, Kim K-W, Krauth-gamer R, Shagdarsuren E, Lira SA, Weissman IL, Weber C, Jung W. CX3CR1 is required for monocyte homeosta-sis and atherogenesis by promoting cell survival. Blood. 2009 Jan 22;113(4):963–72.
16. Butoi E., Gan AM, Manduteanu I, Stan D, Calin M, Pir-vulescu M, Koenen RR, Weber C, Simionescu M. Cross talk between smooth muscle cells and monocytes/acti-vated monocytes via CX3CL1/CX3CR1 axis augments expression of pro-atherogenic molecules. Biochim Bio-phys Acta. 2011;1813(12):2026–35.
17. Mosig S, Rennert K, Krause S, Kzhyshkowska J, Neunü-bel K, Heller R, Funke H. Different functions of mono-cyte subsets in familial hypercholesterolemia: potential function of CD14+ CD16+ monocytes in detoxifcation of oxidized LDL. FASEB J. 2009;23(3):866–74.
18. Cros J, Cagnard N, Woollard K, Patey N, Zhang S-Y, Senechal B, Puel A, Biswas SK, Moshous D, Picard C, Jais JP, D’Cruz D, Casanova JL, Trouillet C, Geiss-mann F. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity. 2010;33(3):375–86.
19. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177(10):7303–11.
20. Zawada AM, Rogacev KS, Rotter B, Winter P, Marell R-R, Fliser D, Heine GH. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood. 2011;118(12):e50–61.
21. Zhu Y, Hojo Y, Ikeda U, Takahashi M, Shimada K. Interaction between monocytes and vascular smooth muscle cells enhances matrix metalloproteinase-1 production. J Cardiovasc Pharmacol. 2000;36(2):152–61.
22. Gan AM, Pirvulescu MM, Stan D, Simion V, Calin M, Manduteanu I, Butoi E. Monocytes and smooth muscle cells cross-talk activates STAT3 and induces resistin and reactive oxygen species and production. J Cell Biochem. 2013;114(10):2273–83.
23. Cai Q, Lanting L, Natarajan R. Growth factors induce monocyte binding to vascular smooth muscle cells: implications for monocyte retention in atherosclerosis. Am J Physiol Cell Physiol. 2004;287(3):C707–14.
24. Williams MWY, Guiffre AK, Fletcher JP. Platelets and smooth muscle cells affecting the differentiation of monocytes. PloS One. 2014;9(2):e88172.
25. Cai Q, Lanting L, Natarajan R. Interaction of monocytes with vascular smooth muscle cells regulates monocyte survival and differentiation through distinct pathways. Arterioscler Thromb Vasc Biol. 2004;24(12):2263–70.
26. Poupel L, Boissonnas A, Hermand P, Dorgham K, Guyon E, Auvynet C, Charles FS, Lesnik P, Deterre P, Comba-diere C. Pharmacological inhibition of the chemokine receptor, CX3CR1, reduces atherosclerosis in mice. Arte-rioscler Thromb Vasc Biol. 2013 Oct;33(10):2297–305.
27. Galkina E, Ley K. Immune and infammatory mechanisms of atherosclerosis (*). Annu Rev Immunol. 2009;27:165–97.
28. Wolfs IMJ, Donners MMPC, de Winther MPJ. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb Haemost. 2011;106(5):763–71.
29. Shiraishi D, Fujiwara Y, Komohara Y, Mizuta H, Takeya M. Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. Bio-chem Biophys Res Commun. 2012 Aug 24;425(2):304–8.
30. Oh J, Riek AE, Weng S, Petty M, Kim D, Colonna M, Cella M, Bernal-Mizrachi C. Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation. J Biol Chem. 2012;287(15):11629–41.
31. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677–86.
32. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel TD, Emde M, Schmidle-ithner L, Ganesan H, Nino-Castro A, Mallmann MR, Labzin L, Theis H, Kraut M, Beyer M, Latz E, Freeman TC, Ulas T, Schultze JL. Transcriptome-based network analysis reveals a spectrum model of human mac-rophage activation. Immunity. 2014;40(2):274–88.
33. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science. 2010;327(5966):656–61.
34. Ostriker A, Horita HN, Poczobutt J, Weiser-Evans MCM, Nemenoff RA. Vascular smooth muscle cell-derived transforming growth factor-β promotes maturation of activated, neointima lesion-like macrophages. Arterioscler Thromb Vasc Biol. 2014;34(4):877–86.
35. Ferri N, Tibolla G, Pirillo A, Cipollone F, Mezzetti A, Pacia S, Corsini A, Catapano AL. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis. 2012;220(2):381–6.
36. Weinert S, Poitz DM, Auffermann-Gretzinger S, Eger L, Herold J, Medunjanin S, Schmeisser A, Strasser RH, Braun-Dullaeus RC. The lysosomal transfer of LDL/ cholesterol from macrophages into vascular smooth muscle cells induces their phenotypic alteration. Cardiovasc Res. 2013;97(3):544–52.
37. Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res. 2012 Jul 15;95(2):156–64.
38. Newby AC, Zaltsman AB. Fibrous cap formation or de-struction—the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc Res. 1999;41(2):345–60.
39. Doran AC, Meller N, McNamara CA. The role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28(5):812–9.
40. De la Cuesta F, Zubiri I, Maroto AS, Posada M, Padial LR, Vivanco F, Alvarez-Llamas G, Barderas MG. Deregulation of smooth muscle cell cytoskeleton within the human atherosclerotic coronary media layer. J Proteomics. 2013;82:155–65.
41. Barlic J, Zhang Y, Murphy PM. Atherogenic lipids induce adhesion of human coronary artery smooth muscle cells to macrophages by up-regulating che-mokine CX3CL1 on smooth muscle cells in a TN-Falpha-NFkappaB-dependent manner. J Biol Chem. 2007;282(26):19167–76.
42. White GE, Tan TCC, John AE, Whatling C, McPheat WL, Greaves DR. Fractalkine has anti- apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling. Cardiovasc Res. 2010;85(4):825–35.
43. Rong JX, Shapiro M, Trogan E, Fisher EA. Transdiffer-entiation of mouse aortic smooth muscle cells to a mac-rophage-like state after cholesterol loading. Proc Natl Acad Sci U S A. 2003;100(23):13531–6.
44. Alexander MR, Murgai M, Moehle CW, Owens GK. Interleukin-1β modulates smooth muscle cell phenotype to a distinct infammatory state relative to PDGF-DD via NF-κB- dependent mechanisms. Physiol Genomics. 2012;44(7):417–29.
45. Lötzer K, Döpping S, Connert S, Gräbner R, Spanbroek R, Lemser B, Beer M, Hildner M, Hehlgans T, van der Wall M, Mebius RE, Lovas A, Randolph GJ, Weih F, Ha-benicht AJ. Mouse aorta smooth muscle cells differentiate into lymphoid tissue organizer-like cells on combined tumor necrosis factor receptor-1/lymphotoxin beta-receptor NF-kappaB signaling. Arterioscler Thromb Vasc Biol. 2010;30(3):395–402.
46. Ali MS, Starke RM, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, Owens GK, Kock WJ, Greig NH, Dumont AS. TNF-α induces phenotypic modulation in cerebral vascular smooth muscle cells: implications for cerebral aneurysm pathology. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2013 Oct;33(10):1564–73.
47. Pidkovka NA, Cherepanova OA, Yoshida T, Alexander MR, Deaton RA, Thomas JA, Leitinger N, Owens GK. Oxidized phospholipids induce phenotypic switching of vascular smooth muscle cells in vivo and in vitro. Circ Res. 2007 Oct 12;101(8):792–801.
48. Kang S-W, Kim J-L, Kwon GT, Lee Y-J, Park JHY, Lim SS, Kang YH. Sensitive fern (Onoclea sensibilis) extract suppresses proliferation and migration of vascular smooth muscle cells infamed by neighboring macro-phages. Biol Pharm Bull. 2011;34(11):1717–23.
49. Roy C, Marceau E, Gera L, Marceau F. An in vitro recon-stitution system to address the mechanism of the vascular expression of the bradykinin B1 receptor in response to angiotensin converting enzyme inhibition. Vascul Pharmacol. 2012;57(1):15–23.
50. Chen L, Frister A, Wang S, Ludwig A, Behr H, Pip-pig S, Li B, Simm A, Hofmann B, Pilowski C, Koch S, Buerke M, Rose-John S, Werdan K, Loppnow H. Interaction of vascular smooth muscle cells and monocytes by soluble factors synergistically enhances IL-6 and MCP-1 production. Am J Physiol Heart Circ Physiol. 2009;296(4):H987–96.
51. Rennick RE, Campbell JH, Campbell GR. Macrophages enhance binding of beta-VLDL and cholesterol ester accumulation in cultured aortic smooth muscle cells. Heart Vessels. 1994;9(1):19–29.
52. Liu H, Yuan L, Xu S, Wang K. Endothelial cell and mac-rophage regulation of vascular smooth muscle cell cal-cifcation modulated by cholestane-3beta, 5alpha, 6beta-triol. Cell Biol Int. 2007;31(9):900–7.
53. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003 Oct;170(2):191–203.
54. Goua M, Mulgrew S, Frank J, Rees D, Sneddon AA, Wahle KWJ. Regulation of adhesion molecule ex-pression in human endothelial and smooth muscle cells by omega-3 fatty acids and conjugated linoleic acids: involvement of the transcription factor NF-kappaB? Prostaglandins Leukot Essent Fatty Acids. 2008;78(1):33–43.
55. Wang X, Feuerstein GZ, Gu JL, Lysko PG, Yue TL. Interleukin-1 beta induces expression of adhesion molecules in human vascular smooth muscle cells and enhances adhesion of leukocytes to smooth muscle cells. Atherosclerosis. 1995;115(1):89–98.
56. Endres M, Laufs U, Merz H, Kaps M. Focal expression of intercellular adhesion molecule-1 in the human carotid bifurcation. Stroke J Cereb Circ. 1997;28(1):77–82.
57. D’Haese JG, Friess H, Ceyhan GO. Therapeutic potential of the chemokine–receptor duo fractalkine/CX3CR1: an update. Expert Opin Ther Targets. 2012;16(6):613–8.
58. Lucas AD, Bursill C, Guzik TJ, Sadowski J, Chan-non KM, Greaves DR. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation. 2003;108(20):2498–504.
59. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006 Apr;86(2):515–81.
60. Marrero MB. Introduction to JAK/STAT signaling and the vasculature. Vascul Pharmacol. 2005 Nov;43(5):307–9.
61. Daniel J-M, Dutzmann J, Bielenberg W, Widmer-Teske R, Gündüz D, Hamm CW, Sedding DG. Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation. Basic Res Car-diol. 2012;107(3):261.
62. Grote K, Luchtefeld M, Schieffer B. JANUS under stress–role of JAK/STAT signaling pathway in vascular diseases. Vascul Pharmacol. 2005;43(5):357–63.
63. Koga J, Aikawa M. Crosstalk between macrophages and smooth muscle cells in atherosclerotic vascular diseases. Vascul Pharmacol. 2012;57(1):24–8.
64. Rius C, Piqueras L, González-Navarro H, Albertos F, Company C, López-Ginés C, Ludwig A, Blanes JI, Mor-cillo EJ, Sanz MJ. Arterial and venous endothelia display differential functional fractalkine (CX3CL1) expression by angiotensin-II. Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):96–104.
65. Fumagalli S, Perego C, Ortolano F, De Simoni M-G. CX-3CR1 defciency induces an early protective infammatory environment in ischemic mice. Glia. 2013;61(6):827–42.
66. Combadière C, Potteaux S, Gao J-L, Esposito B, Casanova S, Lee EJ, Debré P, Tedgui A, Murphy PM, Mallat G. Decreased atherosclerotic lesion formation in CX3CR1/ apolipoprotein E double knockout mice. Circulation. 2003;107(7):1009–16.
67. McDermott DH, Fong AM, Yang Q, Sechler JM, Cupples LA, Merrell MN, Wilson PW, D’Agostino RB, O’Donnell CJ, Patel DD, Murphy PM. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest. 2003 Apr;111(8):1241–50.
68. Kwee L, Baldwin HS, Shen HM, Stewart CL, Buck C, Buck CA, Labow MA. Defective development of the embryonic and extraembryonic circulatory systems in vascular cell adhesion molecule (VCAM-1) defcient mice. Development. 1995;121(2):489–503.
69. Huo Y, Hafezi-Moghadam A, Ley K. Role of vascular cell adhesion molecule-1 and fbronectin connecting seg-ment-1 in monocyte rolling and adhesion on early atherosclerotic lesions. Circ Res. 2000;87(2):153–9.
70. Patel SS, Thiagarajan R, Willerson JT, Yeh ET. Inhibition of alpha4 integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in ApoE-deficient mice. Circulation. 1998;97(1):75–81.
71. Park JG, Ryu SY, Jung IH, Lee YH, Kang KJ, Lee MR, Lee MN, Sonn SK, Lee JH, Lee H, Oh GT, Moon K, Shim H. Evaluation of VCAM-1 antibodies as therapeutic agent for atherosclerosis in apolipoprotein E-def-cient mice. Atherosclerosis. 2013;226(2):356–63.